No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MDGL Madrigal Pharmaceuticals
- 218.380
- +4.890+2.29%
Close Apr 23 16:00 ET
- 217.090
- -1.290-0.59%
Post 19:35 ET
4.58BMarket Cap-10924P/E (TTM)
225.660High210.100Low409.55KVolume212.820Open213.490Pre Close90.16MTurnover3.04%Turnover RatioLossP/E (Static)20.97MShares322.67052wk High11.30P/B2.94BFloat Cap119.76052wk Low--Dividend TTM13.46MShs Float415.800Historical High--Div YieldTTM7.29%Amplitude6.600Historical Low220.139Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results And Host Webcast on May 7, 2024
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2
United Healthcare's Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardinal Health (CAH) and Madrigal Pharmaceuticals (MDGL)
Express News | Madrigal Pharmaceuticals Shares Down 5.7% After BofA Initiates Coverage With Underperform Rating
BofA Skipping Celebration of Madrigal's Rezdiffra -- Market Talk
1121 ET - Madrigal Pharmaceuticals has won many fans on Wall Street since scoring the first FDA approval of a drug to treat the fatty liver disease known as MASH, but Bank of America isn't among them.
Express News | Madrigal Pharmaceuticals Inc : BofA Global Research Initiates Coverage With Underperform Rating; Price Objective $150
Comments
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
2
According to Vantage market estimates for NASH could cross 100 Billion by 2030
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$$Viking Therapeutics(VKTX.US$$Akero Therapeutics(AKRO.US$$89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$$Eli Lilly and Co(LLY.US$$Novo-Nordisk A/S(NVO.US$
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$$Viking Therapeutics(VKTX.US$$Akero Therapeutics(AKRO.US$$89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$$Eli Lilly and Co(LLY.US$$Novo-Nordisk A/S(NVO.US$
6
Evercore ISI analyst Liisa Bayko projects Madrigal's MASH drug sales to exceed $2 billion by 2029, despite competition from anti-obesity medications. The FDA's approval of a MASH drug could boost awareness and patient demand.
2
The FDA's approval of Rezdiffra exceeded analysts' expectations. The absence of a liver biopsy requirement in Rezdiffra's label is expected to positively impact biotech stocks with exposure to MASH.
4
ColumnsToday's Morning Movers and Top Ratings: ADBE, RIVN, ULTA, DASH and More
Morning Movers
Gapping up
$Madrigal Pharmaceuticals(MDGL.US$ stock jumped 25% after the U.S. Food and Drug Administration approved its drug for a fatty liver disease known as non-alcoholic steatohepatitis.
$Rivian Automotive(RIVN.US$ stock rose 3.9% after Piper Sandler upgraded its stance on the EV manufacturer to overweight, citing growing excitement surrounding new product launches.
Gapping down
$Adobe(ADBE.US$ stock f...
Gapping up
$Madrigal Pharmaceuticals(MDGL.US$ stock jumped 25% after the U.S. Food and Drug Administration approved its drug for a fatty liver disease known as non-alcoholic steatohepatitis.
$Rivian Automotive(RIVN.US$ stock rose 3.9% after Piper Sandler upgraded its stance on the EV manufacturer to overweight, citing growing excitement surrounding new product launches.
Gapping down
$Adobe(ADBE.US$ stock f...
27
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg